

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Rainmed Medical Limited

潤邁德醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2297)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED DECEMBER 31, 2023

Reference is made to the annual report of Rainmed Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) for the year ended December 31, 2023 (“**2023 Annual Report**”), published on April 29, 2024. Unless otherwise stated, capitalized terms used in this announcement shall have the same meanings as defined in the 2023 Annual Report.

The Company would like to provide further information in relation to the utilization of the net proceeds of around HK\$78.6 million from Global Offering by December 31, 2023 (the “**Net Proceeds**”). The following table sets out the intended use of the net proceeds and a summary of their utilization as of December 31, 2023:

Intended use of net proceeds	Approximate percentage of total net proceeds	Allocation of net proceeds (HK\$ million)	Balance as of December 31, 2022 (HK\$ million)	Net proceeds utilized in 2023 (HK\$ million)	Balance as of December 31, 2023
The ongoing research and development, further clinical studies, preparation for registration filings, manufacturing and commercialization of our Core Products, namely, caFFR System and caIMR System	80.0%	62.9	35.1	35.1	–
The ongoing research and development, manufacturing and commercialization of our other pipeline products	16.5%	13.0	7.2	7.2	–
For our general working capital and general corporate purposes	3.5%	2.7	–	–	–
Total	100.0%	78.6	42.3	42.3	–

This supplemental information provided in this announcement does not affect other information contained in the 2023 Annual Report. Save as disclosed in this announcement, the contents of the 2023 Annual Report remain unchanged.

By Order of the Board
Rainmed Medical Limited
Huo Yunfei
Chairman of the Board and Executive Director

Hong Kong, September 10, 2024

As at the date of this announcement, the board of directors of the Company comprises Mr. Huo Yunfei, Mr. Lyu Yonghui and Ms. Gu Yang as executive directors, Dr. Huo Yunlong, Mr. Wang Lin and Mr. Heng Lei as non-executive directors, and Mr. Liu Shuen Kong, Mr. Li Ho Man and Mr. Chen Xuefeng as independent non-executive directors.